

# NCI Myelodysplastic Syndromes Symposium

July 12, 2019

## AGENDA

### FRIDAY, JULY 12, 2019

10:30 a.m. **Registration**

11:00 a.m. **Welcome & Introductions**

Steven Pavletic, M.D., M.S., *Center for Cancer Research, NCI*

Naoko Takebe, M.D., Ph.D., *Division of Cancer Treatment and Diagnosis, NCI*

11:05 a.m. **Opening Keynote**

Tom Misteli, Ph.D., *Center for Cancer Research, NCI*

11:20 a.m. **Keynote Lecture—The Role of Innate Immunity in MDS Pathogenesis**

Alan List, M.D., *Moffitt Cancer Center*

### Session 1 **Introduction to MDS**

Moderator: Naoko Takebe, M.D., Ph.D., *Division of Cancer Treatment and Diagnosis, NCI*

12:00 p.m. **WHO MDS Classification**

Katherine Calvo, M.D., Ph.D., *Clinical Center, NIH*

**Overview of MDS Standard Therapy**

Catherine Lai, M.D., *Lombardi Cancer Center*

### Session 2 **From Laboratory to Clinic**

Moderator: Peter Aplan, M.D., *Center for Cancer Research, NCI*

12:25 p.m. **Somatic and Germ Line Mutations in AML**

Paul Liu, M.D., Ph.D., *National Human Genome Research Institute, NIH*

**Current Status and Advances in MRD Measurement**

Christopher Hourigan, M.D., D.Phil., *National Heart, Lung, and Blood Institute*

Laura Dillon Ph.D., *National Heart, Lung, and Blood Institute*

**Preclinical Myeloid Leukemia Models**

Peter Aplan, M.D., *Center for Cancer Research, NCI*

**Novel HMAs and Combinations**

Steven Grant, M.D., *Virginia Commonwealth University*

**CTEP AML/MDS Precision Medicine Initiative**

Rich Little, M.D., *Division of Cancer Treatment and Diagnosis, NCI*

1:30 p.m. Break

## Session 2 **From Laboratory to Clinic (continued)**

Moderator: Nirali Shah, M.D., *Center for Cancer Research, NCI*

2:00 p.m.

### **Heterogeneity in Refractory AML**

Michael Gottesman, M.D., *Center for Cancer Research, NCI*

### **Targeting HMA Refractory MDS**

Daniel Larson, Ph.D., *Center for Cancer Research, NCI*

### **Strategies to Enhance Effects of Cellular Immunotherapy**

Jack Shern, M.D., *Center for Cancer Research, NCI*

### **NK Cell Therapy for Myeloid Leukemia**

Kate Stringaris, M.D., Ph.D., *National Heart, Lung and Blood Institute, NIH*

### **Chemotherapy Induced AML in Modern Era**

Lindsay Morton, Ph.D., *Division of Cancer Epidemiology and Genetics, NCI*

## Session 3 **Active Treatment Protocols**

Moderator: Steven Pavletic, M.D., M.S., *Center for Cancer Research, NCI*

3:00 p.m.

### **DCTD Phase 1 Program**

Geraldine O'Sullivan, M.D., Ph.D., *Division of Cancer Treatment and Diagnosis, NCI*

### **Clofarabine and Bortezomib Phase 1 Study**

Naoko Takebe, M.D., Ph.D., *Division of Cancer Treatment and Diagnosis, NCI*

Sabrina Khan, M.D., MPH, *Center for Cancer Research, CCR*

### **CSF1R Blockade**

Rosandra Kaplan, M.D., *Center for Cancer Research, NCI*

### **MUD RIC Transplant for Hematologic Malignancy**

Steven Pavletic, M.D., M.S., *Center for Cancer Research, NCI*

### **Haplo-Identical Donor Transplant for Hematologic Malignancy**

Christopher Kanakry, M.D., *Center for Cancer Research, NCI*

### **CAR-T Cells for Acute Leukemia**

Nirali Shah, M.D., *Center for Cancer Research, NCI*

## Session 4 **Inherited Leukemia Protocols**

Moderator: Lea Cunningham, M.D., *National Human Genome Research Institute, NCI*

4:20 p.m.

### **Allogeneic Transplant for GATA2 Mutation**

Mark Parta, Ph.D., *National Institute of Allergy and Infectious Diseases, NIH*

### **RUNX1 Clinic and Transplant Protocols**

Lea Cunningham, M.D., Ph.D., *National Human Genome Research Institute, NCI*

### **Other Inherited Leukemias**

Lisa McReynolds, M.D., Ph.D., *Division of Cancer Epidemiology and Genetics, NCI*

5:00 p.m.

Wrap-up and Adjourn